A pharmacist-led collaborative medication management service reduced problems associated with polypharmacy in older adults with chronic kidney disease (CKD).
Older adults with chronic kidney disease (CKD) who present with several comorbidities are more likely to endure polypharmacy, but a pharmacist-led geriatric medication management service (MMS) can improve the quality of medicine use among affected patients, a study showed.
Results from the study, conducted in the Republic of Korea, were published in the International Journal of Environmental Research and Public Health.
The single-center, retrospective, descriptive study recruited 95 patients who had received MMS, which aims to improve the appropriateness of medication use, reduce medication-related harm, and improve clinical outcomes. The study population had received MMS in an ambulatory care nephrology clinic at a teaching hospital between May 2019-December 2019.
On average, patients were aged 74.9 [7.3] years. About 38 patients (40%) had advanced CKD (stage 4 or 5); the most common comorbidities were hypertension, diabetes, and cardiovascular disease.
Patients undergoing MMS received weekly counseling from designated pharmacists. During these sessions, pharmacists recommended general precautions for patients to follow during medication use and encouraged patients to consult their prescribing physicians about deprescribing inappropriate or unnecessary medications.
In addition, pharmacists also interacted with physicians and patients to intervene and resolve drug-related problems (DRPs) throughout the course of the sessions.
Researchers measured several factors to evaluate the overall impact of MMS on the quality of medicine usage, including the number of medications, the number of potentially inappropriate medications (PIMs), and the proportion of patients on PIMs. Researchers also measured the number of central nervous system (CNS)-active drugs, strong anticholinergic agents, and anticholinergic burden among patients. The frequencies and types of DRPs observed were used to evaluate pharmacist interventions.
After evaluating the impact of MMS on the quality of medication use in 87 patients, findings showed:
The reduction of excessive polypharmacy, PIM use, CNS-active drug use, and anticholinergic burden supported the finding that a pharmacist-led collaborative geriatric MMS for older adults with polypharmacy contributed significantly to the improvement of the quality of medication use, concluded the authors.
Reference
Kim, A J., Lee, H., Shin, E., et al. Pharmacist-Led Collaborative Medication Management for the Elderly with Chronic Kidney Disease and Polypharmacy. Int. J. Environ. Res. Public Health. 2021;18(8):4370; doi: 10.3390/ijerph18084370
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More